Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00911820 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03709225 | Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer(MAYA) | completed | N/A | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2022 |
| clinicaltrials |
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02873975 | A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT03087019 | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03773666 | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02871791 | Palbociclib With Everolimus + Exemestane In BC | completed | Phase 1 / Phase 2 | 41 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT03865654 | Individualizing Surveillance Mammography for Older Breast Cancer Survivors | completed | N/A | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02085941 | Image-guided Cryoablation of Head, Neck and Spine Tumors | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT02657343 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | completed | Phase 1 / Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02359838 | Patient-Centered Care for the Older Adult With Hematologic Malignancy | completed | N/A | 160 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | terminated | Phase 2 | 123 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT03858712 | EHR-embedded OCDT in Breast or GI Cancer | completed | N/A | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02677324 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03717480 | Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02698891 | Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | completed | Phase 2 | 127 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03340532 | HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational Videos | completed | N/A | 266 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03910296 | Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain | completed | — | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT00358163 | Trial of PTK787/ZK 222584 Plus Paclitaxel | terminated | Phase 1 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT01516216 | Study of Vitamin D in Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03736746 | Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals | completed | N/A | 54 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02268175 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT00831571 | Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin | completed | — | 112 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT00317603 | Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients | completed | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT00880464 | Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer | completed | Phase 1 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03392090 | SHARE (Sharing Goals and Preferences) Study | completed | N/A | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT03514680 | Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy | completed | N/A | 226 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT00426205 | GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies | completed | N/A | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03137537 | Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. | terminated | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT00925652 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer(ABCDE) | terminated | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT00116142 | Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer | completed | Phase 3 | 350 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03602885 | EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04481672 | Intravenous Magnesium in Patients Receiving Cisplatin | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT00116220 | Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer | completed | Phase 3 | 206 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT02207504 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03316586 | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT03012477 | CISPLATIN + AZD-1775 In Breast Cancer | completed | Phase 2 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03571841 | Sexual Health and Rehabilitation After Ovarian Suppression Treatment | completed | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT00633958 | A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors(FLT) | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02282722 | Improving Informed Consent for Palliative Chemotherapy | completed | N/A | 216 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2021 | clinicaltrials |
| NCT01799135 | Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) | terminated | N/A | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02499497 | A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer | completed | Phase 2 | 114 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03070145 | Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy | completed | N/A | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01965353 | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma(PanRVD) | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 5, 2021 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials